Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 491-498

  Ren, Xinhua S ^a,b   Herz, Lawrence ^b,c   Qian, Shirley ^a,b   Smith, Eric ^b,c   Kazis, Lewis E ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic agents; Medication adherence; Schizophrenia

Indexed keywords

EID: 70449728446     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s6637     Document Type: Article

References (29)

1. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002;63:516-523. (Pubitemid 34680361)
2. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
3. Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv. 2001;52:1248-1250. (Pubitemid 32823200)
4. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003;54:719-723. (Pubitemid 36752965)
5. Kane JM. Drug therapy: schizophrenia. N Engl J Med. 1996;334:34-41.
6. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696. (Pubitemid 29517559)
7. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68. (Pubitemid 29023554)
8. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care. 2001;39:923-933.
9. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154:1-63. (Pubitemid 27152428)
10. Lehman AF, Steinwachs DM. At issue: Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-10. (Pubitemid 28128486)
11. Department of Veterans Affairs. Clinical Guidelines for Management of Persons with Psychoses. Washington, D.C: Veterans Health Administration; 1998.
12. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103-108.
13. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40:630-639.
14. Docherty J, Mahmoud R, Grogg A, Kozma C. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Schizophr Res. 2003;60:281-282.
15. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003. Schizophr Bull. 2004;30:193-217. (Pubitemid 38828528)
16. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
17. Ren XS, Qian S, Lee AF, Herz L, Miller DR, Kazis LE. Treatment persistence: A comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. J Clin Pharm Ther. 2006;31:57-65.
18. Haynes R. Improving patient adherence: state of the art, with a special focus on medication taking for cardiovascular disorders. In: Burke LE, editor. Compliance in Health Care and Research. New York, NY: Futura Publishing Co; 2001:3-21.
19. Sclar DA, A Chin, TL Skaer, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991;13:489-495.
20. Sclar DA, Skaer TL, Chin A, Okamoto MP, Nakahiro RK, Gill MA. Utility of a transdermal delivery system for antihypertensive therapy. Part 2. Am J Med. 2001;91:57S-60S.
21. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Med Care. 1988;26:814-823.
22. Lamoreaux J. The organizational structure for medical information management in the Department of Veterans Affairs: an overview of major health care databases. Med Care. 1996;34:MS31-MS44.
23. Ren XS, Qian S, Kazis LE. An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration. Neuropsychiatr Dis Treat. 2007;3:277-284. (Pubitemid 46864066)
24. McCombs JS, Nichol MB, Stimmel GL. Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry. 1999;60 Suppl 19:5-11. (Pubitemid 29446944)
25. Cramer JA, Rosenheck P. Enhancing medication compliance for people with serious mental illnesses. J Nerv Ment Disord. 1999;187:53-55.
26. Citrome L, Volavska J. Optimal dosing of atypical anti-psychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10:280-291.
27. Weiden P, Zygmund A. The road back: working with the severely mentally ill. Journal of Practical Psychiatry and Behavioral Health. 1997;3:106-110.
28. Ren XS, Lee AF, Huang YH, Miller DR, Qian S, Kazis LE. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther. 2005a;30:65-71. (Pubitemid 41602093)
29. Ren XS, Kazis LE, Lee AF, et al. Patients' characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia. Schizophr Res. 2005b;77:167-177. (Pubitemid 41112210)